ImmPort Blog

HIPC 2018 Sub-committee meeting blog

December 2018 HIPC Subcommittee Meeting The Human Immune Profiling Consortium HIPC 2018 Subcommittee annual meeting provided an opportunity for the Assay, Bioinformatics and Clinical subcommittees to report on their progress, discuss goals, and refine implementation details. ImmPort works with the HIPC committees to implement their recommendations and guidelines for data acquisition descriptions. The recent addition of immune exposures descriptive attributes for subjects was a collaboration with the bioinformatics and clinical groups to use ontological terms to describe the nature of immune exposures in terms of vaccination, disease, vaccine type and subject disease status.

Read more →

The Accelerating Medicines Partnership (AMP) program, a public-private effort aimed at improving the identification of drug targets and speed the development of new drugs. Participants include the National Institutes of Health (NIH), Foundation for NIH, biopharmaceutical firms as well as non-profit organizations The NIH announced on February 21, 2018 in the NIH News Release the release of AMP data from ImmPort. Data from the Lupus and Rheumatoid Arthritis (AMP/SLE) pilot projects is now available in ImmPort as SDY997, SDY998 & SDY999.

Read more →

CHIKV Immune Profiling

A data-drive model of pediatric immune reaction to chikungunya virus infection. A recently published study used multiple profiling techniques in a comprehensive assessment of natural pediatric infection with CHIKV. Researchers compared the acute and convalescent phases of 42 pediatric cases of CHIKV from a hospital-based study in Nicaragua. The analysis combined RNA-seq, CyTOF, and multiplex bead array ELISA data with semi-supervised classification and clustering methods in a systems immunology approach to identify changes in cell subpopulation frequencies, gene expression, and serum cytokine/chemokine concentrations during acute CHIKV infection.

Read more →

MetaCyto

MetaCyto: a tool for meta-analysis of flow cytometry and mass cytometry data Meta-analysis of existing data across different studies offers multiple benefits, including increased statistical power and more robust conclusions. These benefits have been shown by many studies in areas such as genomics, cancer biology, and clinical research, and have led to important new biomedical findings. With the recent advances in high-throughput cytometry technologies, the immune system can be characterized at the single-cell level with up to 45 parameters, minimizing the technical limitations and allowing capture of more valuable information from immunology studies.

Read more →